BIDEA develops point-of-care in-vitro diagnostic devices for the early detection of endometrial cancer.
BIDEA offers tests that will not only impact the quality of life of patients but can also reduce costs to hospitals, health insurance companies, and government agencies. Their proposed screening technology is expected to help gynaecologists in hospitals and in private practices provide a complete diagnosis in less time, reducing the number of visits and endometrial cancer incidence through early detection, especially in women over the age of 50.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 29, 2017 | Grant | $225K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |